menu
    • menu

    Company profile for KalVista Pharmaceuticals

    NEW Drugs in Dev: 3
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet need. Our initial focus is on inhibitors of plasma kallikrein, which is an important component of the body’s inflammatory response and which, in excess, can lead to increased vascular permeability, edema and inflammation. We have developed...
    KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet need. Our initial focus is on inhibitors of plasma kallikrein, which is an important component of the body’s inflammatory response and which, in excess, can lead to increased vascular permeability, edema and inflammation. We have developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    KalVista PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    55 Cambridge Pkwy Cambridge, Massachusetts 02142
    Telephone
    Telephone
    1 (857) 999 0075
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.kalvista.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/kalvista-pharmaceuticals-limited/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/kalvista?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Chiesi Snaps Up Kalvista For $1.9B, Betting Big On Rare Disease
    Chiesi Snaps Up Kalvista For $1.9B, Betting Big On Rare Disease

    30 Apr 2026

    // BIOSPACE

    https://www.biospace.com/business/chiesi-snaps-up-kalvista-for-1-9b-betting-big-on-rare-disease-med-ekterly

    BIOSPACE
    30 Apr 2026
    Share Share
    Kalvista Pharma to Present at 25th Needham Conference
    Kalvista Pharma to Present at 25th Needham Conference

    08 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-08/kalvista-pharmaceuticals-to-present-at-the-25th-annual-needham-virtual-healthcare-conference

    PHARMIWEB
    08 Apr 2026
    Share Share
    KalVista Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
    KalVista Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)

    02 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260402497914/en/KalVista-Pharmaceuticals-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4

    BUSINESSWIRE
    02 Apr 2026
    Share Share
    KalVista Pharma Reports Inducement Grants Under Nasdaq Rules
    KalVista Pharma Reports Inducement Grants Under Nasdaq Rules

    02 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-02/kalvista-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4

    PHARMIWEB
    02 Apr 2026
    Share Share
    KalVista EKTERLY Ph3 KONFIDENT-KID Shows Positive Interim Data
    KalVista EKTERLY Ph3 KONFIDENT-KID Shows Positive Interim Data

    30 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260330460675/en/KalVista-Pharmaceuticals-Announces-Positive-Interim-Phase-3-Data-From-KONFIDENT-KID-Trial-of-EKTERLY-sebetralstat-for-Children-Aged-2-11-Years-at-the-2026-Global-Angioedema-Leadership-Conference

    BUSINESSWIRE
    30 Mar 2026
    Share Share
    Kalvista Pharma Reveals Fy2025 Financials & Corporate Update
    Kalvista Pharma Reveals Fy2025 Financials & Corporate Update

    25 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-25/kalvista-pharmaceuticals-reports-eight-months-fiscal-year-2025-financial-results-and-provides-corpor

    PHARMIWEB
    25 Mar 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search